# Lindus Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lindus-health

- Industry: Healthcare IT
- Headquarters: London, UK
- Website: www.lindushealth.com
- Total disclosed funding: $78M
- Latest round: Series B (Jan 22, 2025)
- Investors on record: 10

## About

Lindus Health Limited, based in the UK, specializes in providing innovative clinical trial solutions that streamline the research and development of new therapies in the life sciences sector.Founded in 2021 and headquartered in London, UK, Lindus Health Limited focuses on enhancing clinical trial efficiency. The company was established by Grace Currie, Meri Beckwith, Michael Young, and Nik Haldimann. Lindus Health has completed 5 deals, with the most recent being a Series B funding round on January 22, 2025, where they raised USD 55.00 mn led by Balderton Capital, with participation from other investors including Creandum, Firstminute Capital, Seedcamp, and Visionaries Club. This funding round brought the total amount raised by the company to USD 55.00 mn.Lindus Health offers a comprehensive suite of clinical trial solutions designed to expedite the research and development of new therapies within the life sciences sector. The company's core offerings include end-to-end clinical trial management, leveraging their proprietary Citrus™ platform, which integrates electronic data capture (EDC), clinical trial management system (CTMS), and real-time monitoring capabilities. Their services facilitate site management, patient recruitment, and protocol design, allowing for a streamlined process that reduces the time and complexity traditionally associated with clinical trials. Lindus Health serves a diverse clientele, including biotechnology and pharmaceutical companies globally, with particular emphasis on the US, UK, and European markets. Through their agile technology and innovative recruitment methods, Lindus Health addresses critical pain points in clinical trials, ultimately aiming to bring new treatments to market faster and more efficiently.Revenue generation at Lindus Health is anchored in a fixed milestone, pay-on-results business model, which aligns financial incentives with client outcomes. This structure enables clients to engage in partnerships that minimize unexpected costs and timeline delays during clinical trials. The company primarily operates on a B2B basis, providing services directly to biotech and pharmaceutical firms, which benefit from Lindus Health's consolidated offerings. Although specific pricing details are proprietary, the structure typically involves payment tied to project milestones, ensuring that clients pay based on results achieved rather than traditional hourly billing. Lindus Health’s commitment to delivering quality and timely results supports its revenue framework, enhancing client satisfaction and encouraging repeat engagements.In January 2025, Lindus Health Limited successfully raised USD 55.00 mn in Series B funding, led by Balderton Capital, to advance the development of its clinical trial solutions and expand its testing capabilities. The company is focused on releasing new products designed to address specific client needs in clinical trials and anticipates launching these innovations over the next year. Lindus Health is also planning to expand its operations into new geographic markets, particularly targeting opportunities in Asia and Australia by the end of 2025, leveraging the recent funding to support these strategic initiatives.

## Funding rounds

- Series B, Jan 22, 2025, $55M — Creandum, Balderton Capital, Seedcamp, Firstminute Capital, Visionaries Club
- Series A, Aug 16, 2023, $18M — Creandum, Seedcamp, Salica Investments, Firstminute Capital, Calm/Storm Ventures, Page One Ventures, Amino Collective
- Seed, Nov 5, 2021, $4.5M — Seedcamp, Salica Investments, Firstminute Capital, Presight Capital, Calm/Storm Ventures, Amino Collective

## Investors

- Seedcamp (https://capitalatlas.ai/funds/seedcamp) — Seed, Series A, Series B
- Salica Investments (https://capitalatlas.ai/funds/salica-investments) — Seed, Series A
- Firstminute Capital (https://capitalatlas.ai/funds/firstminute-capital) — Seed, Series A, Series B
- Presight Capital — Seed
- Calm/Storm Ventures (https://capitalatlas.ai/funds/calm-storm-ventures) — Seed, Series A
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Seed, Series A
- Creandum (https://capitalatlas.ai/funds/creandum) — Series A, Series B
- Page One Ventures (https://capitalatlas.ai/funds/page-one-ventures) — Series A
- Balderton Capital (https://capitalatlas.ai/funds/balderton-capital) — Series B
- Visionaries Club (https://capitalatlas.ai/funds/visionaries-club) — Series B